



## LICENCE WITHDRAWN

Please refer to the European Medicines Agency website for further information

### Final Appraisal Recommendation

Advice No: 0913 – May 2013

**Ferumoxytol (Rienso<sup>®</sup>▼) 30 mg/ml solution for injection**

**Submission by Takeda UK Ltd**

#### Recommendation of AWMSG

**Ferumoxytol (Rienso<sup>®</sup>▼) is recommended as an option for restricted use within NHS Wales.**

**Ferumoxytol (Rienso<sup>®</sup>▼) should only be used for the intravenous treatment of iron deficiency anaemia in non-haemodialysis dependent adult chronic kidney disease patients when oral iron is ineffective or cannot be used.**

**Ferumoxytol (Rienso<sup>®</sup>▼) is not recommended for use within NHS Wales outside of this subpopulation of patients.**

**The diagnosis of iron deficiency must be based on appropriate laboratory tests.**

#### Additional note:

- Patients currently receiving ferumoxytol (Rienso<sup>®</sup>▼) who do not meet the criteria for treatment outlined in the recommendation above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 145), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

This recommendation was ratified by the Minister for Health and Social Services in July 2013 and will be considered for review in July 2016.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0913:  
Ferumoxyl (Rienso<sup>®</sup>) 30 mg/ml solution for injection. May 2013.